In the News
PULMONX ANNOUNCES THAT UNITEDHEALTHCARE, THE LARGEST COMMERCIAL INSURER IN THE UNITED STATES, HAS LIFTED COVERAGE RESTRICTIONS ON THE ZEPHYR VALVE, A MINIMALLY-INVASIVE TREATMENT OPTION FOR SEVERE EMPHYSEMA (COPD)
November 18, 2019
Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that UnitedHealthcare®, the largest commercial insurer in the United States, has lifted coverage restrictions on endobronchial valves, a minimally-invasive treatment option for severe emphysema, a form of COPD.
THE NEW 2020 REPORT FROM THE GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD) GIVES HIGHEST EVIDENCE RATING TO ENDOBRONCHIAL VALVES, INCLUDING THE ZEPHYR VALVE, FOR TREATMENT OF EMPHYSEMA / COPD
November 11, 2019
Global Initiative for Chronic Obstructive Disease (GOLD) has upgraded the evidence level rating for bronchoscopic lung volume reduction (BLVR) with endobronchial valves, including the Zephyr Valve, for the treatment of emphysema and COPD.
PULMONX ANNOUNCES THAT PRIORITY HEALTH NOW COVERS THE ZEPHYR VALVE, A LESS INVASIVE TREATMENT OPTION FOR SEVERE EMPHYSEMA (COPD)
August 28, 2019
Pulmonx Corporation, a leader in diagnostic and therapeutic pulmonary device technologies, announced today that its Zephyr® Valve has received positive coverage from Humana® under its new endobronchial valve (EBV) coverage policy.
PULMONX CLOSES $65 MILLION FINANCING AND ADDS CHIEF FINANCIAL OFFICER
May 10, 2019
Pulmonx Corporation, a leader in diagnostic and therapeutic pulmonary device technologies, announced today that its Zephyr® Valve has received positive coverage from Humana® under its new endobronchial valve (EBV) coverage policy.
PULMONX ANNOUNCES THAT HUMANA HAS ISSUED A POSITIVE COVERAGE POLICY FOR THE ZEPHYR VALVE, A LESS INVASIVE TREATMENT OPTION FOR SEVERE EMPHYSEMA (COPD)
April 30, 2019
Pulmonx Corporation, a leader in diagnostic and therapeutic pulmonary device technologies, announced today that its Zephyr® Valve has received positive coverage from Humana® under its new endobronchial valve (EBV) coverage policy.
HOUSTON METHODIST FIRST IN TEXAS, AND SECOND IN THE COUNTRY, TO OFFER NEW VALVE TREATMENT FOR EMPHYSEMA
January 29, 2019
Houston Methodist is the first hospital in Texas to offer a new minimally invasive treatment for emphysema, a severe form of COPD. The procedure improves patients’ quality of life by allowing them to breathe easier, be less short of breath, and be more active and energetic. The treatment, using the Zephyr® Valve System, is groundbreaking because it is the first FDA approved procedure for emphysema that is minimally invasive (no incision or cutting required).
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) ISSUES NEW GUIDELINES FOR COPD, RECOMMENDING SEVERE PATIENTS BE EVALUATED FOR BRONCHOSCOPIC LUNG VOLUME REDUCTION
December 12, 2018
The US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients.
PULMONX ANNOUNCES THAT ONE OF THE LEADING HEALTH CARE PROVIDERS IN THE UNITED STATES NOW COVERS THE ZEPHYR VALVE FOR BRONCHSCOPIC LUNG VOLUME REDUCTION IN PATIENTS WITH SEVERE EMPHYSEMA
November 27, 2018
The US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients.
FDA APPROVES ZEPHYR ENDOBRONCHIAL VALVE FOR TREATING SEVERE EMPHYSEMA
June 29, 2018
The US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients.
ZEPHYR ENDOBRONCHIAL VALVES IMPROVE BREATHING, QUALITY OF LIFE AND ACTIVITY FOR SEVERE EMPHYSEMA PATIENTS IN US PIVOTAL TRIAL
May 22, 2018
Pulmonx®Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD).